Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
NCT ID: NCT00127270
Last Updated: 2008-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
395 participants
INTERVENTIONAL
2005-05-31
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
NCT00366002
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
NCT00171184
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
NCT00170755
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
NCT01175382
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
NCT00171145
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Darifenacin
Darifenacin
Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
2
Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder
Darifenacin
Darifenacin tablets 7,5 mg or 15 mg once daily
Behavioral therapy
Behavioral Modification Programme for symptoms of overactive bladder
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Darifenacin
Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
Darifenacin
Darifenacin tablets 7,5 mg or 15 mg once daily
Behavioral therapy
Behavioral Modification Programme for symptoms of overactive bladder
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Capable of independent toileting and completing a micturition diary
* Able to comprehend English and follow study procedures and instructions
Exclusion Criteria
* Urine flow rate (Qmax) \<10ml/sec for males only
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Procter and Gamble
INDUSTRY
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Novartis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals Corp.
Role: STUDY_DIRECTOR
Novartis Pharmaceutical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Research Center
Birmingham, Alabama, United States
Quality of Life Medical & Research
Tucson, Arizona, United States
UCLA - Urology Sciences Research Foundation
Culver City, California, United States
San Diego Center for Urology Care
La Mesa, California, United States
Orange County Urology Associates
Laguna Woods, California, United States
Atlantic Urology Medical Group
Long Beach, California, United States
California Professional Research
Newport Beach, California, United States
Private Practice
North Hollywood, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Encompass Clinical Research
Spring Valley, California, United States
Western Clinical Research
Torrance, California, United States
Urology Research Options
Aurora, Colorado, United States
Western Urologic Associates
Wheat Ridge, Colorado, United States
Connecticut Clinical Research Center
Waterbury, Connecticut, United States
South Florida Medical Research
Aventura, Florida, United States
Advance Research Institute
New Port Richey, Florida, United States
Florida Healthcare Research
Ocala, Florida, United States
Winter Park Urology Associates
Orlando, Florida, United States
Atlanta Medical Research Institute
Alpharetta, Georgia, United States
Shepard Center
Atlanta, Georgia, United States
Deerpath Physicians Group
Gurnee, Illinois, United States
RMD Clinical Research Institute
Melrose Park, Illinois, United States
Southern Illinois Clinical Research Center
O'Fallon, Illinois, United States
Springfield Clinic
Springfield, Illinois, United States
Welborn Clinic
Evansville, Indiana, United States
Urology of Indiana
Indianapolis, Indiana, United States
Metropolitan Urology
Jeffersonville, Indiana, United States
Urologic Surgery Associates
Overland Park, Kansas, United States
Pratt Internal Medicine Group
Pratt, Kansas, United States
Cotton-O'Neil Clinic
Topeka, Kansas, United States
Hearthland Research Associates
Wichita, Kansas, United States
Adult and Pediatric Urology
Saint Cloud, Minnesota, United States
Mississippi Urology Clinical Research
Jackson, Mississippi, United States
PPS Clinical Research
St Louis, Missouri, United States
Washing Univ School of Medicine - Urologic Research Center
St Louis, Missouri, United States
Women's Clinic of Lincoln
Lincoln, Nebraska, United States
Quality Clinical Research
Omaha, Nebraska, United States
Meridian Clinical Research
Omaha, Nebraska, United States
Lawrenceville Urology
Lawrenceville, New Jersey, United States
Center for Urologic Care
Voorhees Township, New Jersey, United States
Central New York Clinical Research
Manlius, New York, United States
Hudson Valley Urology
Poughkeepsie, New York, United States
Jacobi Medical Center
The Bronx, New York, United States
Northeast Urology Research
Concord, North Carolina, United States
Multi Specialty Research Associates of NC
Raleigh, North Carolina, United States
Piedmont Medical Research Associates
Winston-Salem, North Carolina, United States
Private Practice
Edmond, Oklahoma, United States
Southern Oregon Health and Wellness
Medford, Oregon, United States
Portland Clinic
Portland, Oregon, United States
Williamette Women's Health
Tualatin, Oregon, United States
Univ. of Pittsburgh Medical Center- Dept of Urology
Pittsburgh, Pennsylvania, United States
Research Protocol Management Specialists
Pittsburgh, Pennsylvania, United States
South Carolina Clinical Research Center
Columbia, South Carolina, United States
Doctors for Women
Nashville, Tennessee, United States
Medical Arts Clinic
Corsicana, Texas, United States
Radiant Research
Dallas, Texas, United States
Urology Clinics of North Texas
Dallas, Texas, United States
Advances in Health
Houston, Texas, United States
Kelsey Seybold Research Foundation
Houston, Texas, United States
R/D Clinical Research
Lake Jackson, Texas, United States
Progressive Clinical Research
Centerville, Utah, United States
Intermountain Clinical Research
Salt Lake City, Utah, United States
Salt Lake Research
Salt Lake City, Utah, United States
Virginia Urology
Richmond, Virginia, United States
East Coast Clinical Research
Virginia Beach, Virginia, United States
Radiant Research
Lakewood, Washington, United States
Valley Women's Clinic
Renton, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Funada S, Yoshioka T, Luo Y, Sato A, Akamatsu S, Watanabe N. Bladder training for treating overactive bladder in adults. Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD013571. doi: 10.1002/14651858.CD013571.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDAR328AUS01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.